PULM - Pulmatrix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5100
-0.2900 (-16.11%)
At close: 4:00PM EDT

1.4600 -0.05 (-3.31%)
After hours: 4:46PM EDT

Stock chart is not supported by your current browser
Previous Close1.8000
Open1.6000
Bid1.4600 x 1000
Ask1.5700 x 800
Day's Range1.4100 - 1.6347
52 Week Range0.7200 - 11.5000
Volume890,434
Avg. Volume731,220
Market Cap12.122M
Beta (3Y Monthly)2.60
PE Ratio (TTM)N/A
EPS (TTM)-4.9830
Earnings DateMay 2, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Pulmatrix to Participate in Upcoming Investor Conferences
    PR Newswire6 days ago

    Pulmatrix to Participate in Upcoming Investor Conferences

    Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in development to treat Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD).

  • Pulmatrix Regains NASDAQ Compliance
    PR Newswire8 days ago

    Pulmatrix Regains NASDAQ Compliance

    The letter received noted that for 10 consecutive business days, from February 26, 2019 to March 11, 2019, the closing bid price of the Company's common stock was $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is closed. Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in development to treat Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD).

  • ACCESSWIRE12 days ago

    These Four Tech Stocks Could Set The Pace On Friday

    Over the course of the last few months, we've seen tech companies cause quite a commotion in the market because of their determination to use design-thinking and strategically develop products and ideas for the betterment of consumers. ParcelPal Technology Inc (PTNYF) (PKG), MicroVision Inc (MVIS), Pulmatrix Inc (PULM), and Xunlei Limited (XNET) represent 4 tech stocks on the rise on Friday. ParcelPal Technology Inc (PTNYF) (PKG) is a technology-driven logistics company purposed with connecting consumers to the goods they love.

  • Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline
    PR Newswire29 days ago

    Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline

    LEXINGTON, Mass. , Feb. 19, 2019 /PRNewswire/ --  Pulmatrix, Inc . (NASDAQ: PULM) today announces 2018 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary ...

  • Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs
    PR Newswirelast month

    Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs

    LEXINGTON, Mass., Feb. 12, 2019 /PRNewswire/ -- Pulmatrix, Inc. (PULM) has been awarded five new patents that expand the intellectual property protection for Pulmatrix's PUR1800 and PUR5700 programs.  These patents expand the intellectual property protection for Pulmatrix's novel Inhaled Narrow Spectrum Kinase Inhibitors which were in licensed from Janssen in June 2017. The US Patent Office granted US Patent No. 9,993,478 B2, which claims dry powder formulations that contain certain narrow spectrum kinase inhibitors as the active pharmaceutical ingredient and cover dry powder formulations of the in licensed compound RV-1162.  RV-1162 is the active pharmaceutical ingredient in PUR1800.

  • Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market
    PR Newswirelast month

    Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market

    LEXINGTON, Mass., Feb. 8, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 1,706,484 shares of common stock at a price of $1.465 per share in a registered direct offering priced at-the-market, resulting in total gross proceeds of approximately $2.5 million. The Company also agreed to issue to the investors unregistered warrants to purchase up to 1,706,484 shares of common stock. The warrants have an exercise price of $1.34 per share of common stock, will be exercisable immediately and will expire five and one-half years following the date of issuance.

  • Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
    PR Newswirelast month

    Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study

    Pulmatrix notified of FDA's authorization to proceed for a Phase 2 study of Pulmazole (inhaled itraconazole) in asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA) LEXINGTON, Mass. , ...

  • ACCESSWIRElast month

    4 Biotech Stocks Making Moves on Wednesday (2/6/19)

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Pulmatrix Inc (PULM), MacroGenics Inc (MGNX), and Proteostasis Therapeutics Inc (PTI) represent four biotech companies creating nuanced approaches to further the advancement of modern medicine. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments which demonstrate Premier's dedication to the betterment of the biotech industry, and more importantly, to consumers looking to enhance their quality of life. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced at the tail-end of last month that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1
    PR Newswirelast month

    Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1

    LEXINGTON, Mass., Feb. 6, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the termination of its previously planned underwritten public offering, with Oppenheimer & Co., Inc. as sole bookrunner, pursuant to a Registration Statement on Form S-1, File No. 333-229092. Pulmatrix filed with the Securities and Exchange Commission (the "SEC") a request to withdraw the Registration Statement, initially filed with the SEC on December 28, 2018. The Company requested to withdraw the Registration Statement due to market conditions and for strategic reasons.

  • Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split
    PR Newswirelast month

    Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split

    LEXINGTON, Mass., Feb. 5, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced a 1-for-10 reverse split of its common stock, effective as of 5:00 pm Eastern Time, February 5, 2019. Beginning on February 6, 2019, the Company's common stock will trade on the NASDAQ Capital Market on a split adjusted basis. At the Company's 2018 annual meeting of stockholders on June 5, 2018, the Company's stockholders authorized the Board of Directors, in its discretion but prior to the annual meeting of our stockholders in 2019, to amend the Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split at a ratio in the range of 1-for-4 to 1-for-10.

  • Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock
    PR Newswirelast month

    Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock

    LEXINGTON, Mass., Feb. 5, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the closing and funding of its previously announced underwritten public offering of 5,323,530 shares of its common stock at a price to the public of $0.17 per share. Pulmatrix currently intends to use the net proceeds from the offering for working capital and general corporate purposes. A shelf registration statement on Form S-3 (Registration No. 333-212546) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and was declared effective on August 3, 2016.

  • Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock
    PR Newswire2 months ago

    Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock

    LEXINGTON, Mass., Jan. 30, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the pricing of an underwritten public offering of 5,323,530 shares of its common stock at a price to the public of $0.17 per share. Pulmatrix expects to receive aggregate gross proceeds of approximately $905,000 from the offering. The offering is expected to close on or about February 4, 2019, subject to customary closing conditions.

  • Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock
    PR Newswire2 months ago

    Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock

    LEXINGTON, Mass., Jan. 30, 2019 /PRNewswire/ – Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

  • Pulmatrix Announces $3.0 Million Registered Direct Offering
    PR Newswire4 months ago

    Pulmatrix Announces $3.0 Million Registered Direct Offering

    LEXINGTON, Mass., Nov. 29, 2018 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 9,375,000 shares of common stock (or common stock equivalents) at a price of $0.32 per share in a registered direct offering, resulting in total gross proceeds of $3.0 million. The Company also agreed to issue unregistered warrants to the investor in a concurrent private placement to purchase up to 1 share of common stock for each share or common stock (or common stock equivalent) purchased with an exercise price of $0.39 per share.

  • Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
    PR Newswire4 months ago

    Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    LEXINGTON, Mass., Nov. 21, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM) announced the results of the completed first-in-human study of Pulmazole (PUR1900) — an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

  • Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology
    PR Newswire4 months ago

    Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology

    LEXINGTON, Mass., Nov. 15, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently completed phase 1/1b clinical trial of Pulmazole, an inhaled dry-powder iSPERSE™ formulation of itraconazole, at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology in Seattle, Washington on November 17, 2018.

  • Pulmatrix Reports Q3 2018 Results
    PR Newswire4 months ago

    Pulmatrix Reports Q3 2018 Results

    LEXINGTON, Mass. , Nov. 14, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM) today reported its third quarter results. "We remain focused on advancing the clinical development of our Pulmazole ...

  • Who Owns Most Of Pulmatrix Inc (NASDAQ:PULM)?
    Simply Wall St.6 months ago

    Who Owns Most Of Pulmatrix Inc (NASDAQ:PULM)?

    A look at the shareholders of Pulmatrix Inc (NASDAQ:PULM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...

  • Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress
    PR Newswire6 months ago

    Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress

    LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present preclinical data on the anti-inflammatory activity of PUR1800 (RV1162) at the ERS International Congress 2018 in Paris, France. Aidan Curran, PhD and Senior Director, Research at Pulmatrix Inc will present preclinical data in an abstract entitled "PUR1800 (RV1162), a novel narrow spectrum kinase Inhibitor, but not fluticasone, reduces TNFα-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients" at 8:30AM on Wednesday, September 19.

  • Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018
    PR Newswire7 months ago

    Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018

    As part of the presentation, Robert Clarke, Ph.D., chief executive officer of Pulmatrix, will provide an update on the Company's business and its pipeline of inhaled therapeutics. Among the highlights of the presentation will be positive data from a phase 1/1b clinical study of Pulmatrix's Pulmazole, an inhaled an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma. Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology.

  • Pulmatrix Reports Q2 2018 Results
    PR Newswire8 months ago

    Pulmatrix Reports Q2 2018 Results

    LEXINGTON, Mass. , Aug. 3, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. "We are pleased with the preliminary results of the three-part Phase 1/ 1b ...

  • Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development
    PR Newswire8 months ago

    Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development

    Members include experts in both clinical research and management of Allergic Bronchopulmonary Aspergillosis and Asthma LEXINGTON, Mass. , July 23, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM), ...